SANA•benzinga•
Sana Biotechnology To Prioritize And Increase Investment In Preclinical Development On Type 1 Diabetes Program And B-cell Mediated Autoimmune Diseases; Will Suspend Development Of SC291 And SC379
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 4, 2024 by benzinga